In this report, we describe the ability of NVP-AUY922 to radiosensitize cervical, colorectal and HNSCC cell lines with greater potency than any previously reported HSP90 inhibitor. This evidence concerns the gene HSP90AA1 and head and neck squamous cell carcinoma.